Skip to main content
. 2021 Apr 30;11:664927. doi: 10.3389/fonc.2021.664927

Figure 4.

Figure 4

Inhibition of IL-6 blocks tumor burden in Apcmin/+Ripk3-/- mice. (A) Scheme for anti-IL6R antibody treatment in Apcmin/+Ripk3-/- mice. (B) Four-week-old Apcmin/+Ripk3-/- mice were injected with anti-IL6R antibody with at a dosage of 4 mg/kg weekly for 10 weeks. The clinical scores were monitored. (C) Numbers of intestinal tumors in Un- or anti-IL6R-treated Apcmin/+Ripk3-/- mice. (D, E) Hematocrit (D) and thymus weight (E) of Apcmin/+Ripk3-/- mice after anti-IL6R therapy for 10 weeks. (F) Intestinal tumors were collected from PBS and anti-IL6R-treated Apcmin/+Ripk3-/- mice. The levels of p-STAT3 were determined by western blotting. (G, H) The expression of STAT3 target genes expression in PBS and anti-IL6R-treated Apcmin/+Ripk3-/- intestinal tumors. *p < 0.05, ***p < 0.001 versus Un-treated Apcmin/+Ripk3-/- mice.